Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 14Prostatic Neoplasms 10Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3HIV Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma, Kaposi 1Recurrence 1Pain 1Myeloid Malignancies 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Dendritic Cell Sarcoma, Interdigitating 1Androgen-independent Prostate Cancer 1

Interventions

ibrutinib 6pirtobrutinib 2blinatumomab 2tozasertib 1ofatumumab 1oblimersen 1obinutuzumab 1mocetinostat 1lucatumumab 1forodesine 1fenebrutinib 1enzastaurin 1Mitoxantrone 1Epoetin Alfa 1Bendamustine Hydrochloride 1Antineoplastic Agents 1ARQ531 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Lymphoid × Mitoxantrone × Clear all
NCT02462265 2018-04-18

Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients

Oshadi Drug Administration

Phase 2 Suspended
15 enrolled
Other hematologic neoplasm

Leukemia, Lymphoid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡